Abstract |
Lipoprotein glomerulopathy is an inherited renal disease characterized by unique lipoprotein thrombi in the glomerulus and is associated with the APOE mutation. Hu and colleagues investigated the genetic and clinical features of a large group of patients with lipoprotein glomerulopathy who carried APOE Kyoto, a major APOE variant. Their findings suggest its descent through a founder effect. Fibrate therapy in this group showed favorable results in the patient and renal survival rates.
|
Authors | Takao Saito, Akira Matsunaga |
Journal | Kidney international
(Kidney Int)
Vol. 85
Issue 2
Pg. 243-5
(Feb 2014)
ISSN: 1523-1755 [Electronic] United States |
PMID | 24487366
(Publication Type: Journal Article, Comment)
|
Chemical References |
- Apolipoprotein E2
- Hypolipidemic Agents
- apolipoprotein E2 (Kyoto)
- Fenofibrate
|
Topics |
- Apolipoprotein E2
(genetics)
- Female
- Fenofibrate
(therapeutic use)
- Humans
- Hypolipidemic Agents
(therapeutic use)
- Kidney
(drug effects)
- Kidney Diseases
(drug therapy, genetics)
- Male
- Mutation
|